Guizhou Taibang Biological Products

Guizhou Taibang Biological Products Co., Ltd. is a Chinese plasma-based biopharmaceutical company founded in 2002, specializing in critical therapies for life-threatening diseases. It operates a GMP-certified manufacturing facility in Guizhou Province. The company has multiple approved plasma-based products in China, including human prothrombin complex concentrate, human immunoglobulin, human coagulation factor IX, human fibrinogen, and human coagulation factor VIII. Its pipeline includes Factor VIII in Phase 3, Anthrax Immune Globulin in Phase 1, a new generation IVIG, human antithrombin III, human cytomegalovirus immunoglobulin, and human fibrin sealant in clinical trials. It was fully acquired by China Biologic Products Holdings by 2016.